Novo Nordisk shares dive 9% after heart medicine fails trial

Shares of Novo Nordisk nosedived as much as 10% after the drugmaker said a late-stage heart drug trial failed to reduce major cardiovascular events compared to a placebo. While the experimental medicine, ziltivekimab, did show some biological effect, it didn’t translate into a statistically meaningful reduction in so-called MACE, defined as cardiovascular death, non-fatal heart attack…

Read More